The American Society for Clinical Oncology annual meeting doesn't start until the end of this month, but investors will get a little sneak peek of what to expect when abstracts for the meeting are released at 5 p.m. Eastern on Wednesday.
In the video below, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss what they're looking forward to seeing at ASCO, including AstraZeneca's (AZN 0.36%) phase 2 data for its PARP inhibitor olaparib used alone or in combination with cediranib in patients with ovarian cancer, Johnson & Johnson (JNJ 0.55%) and Pharmacyclics' (NASDAQ: PCYC) phase 3 data testing Imbruvica verse GlaxoSmithKline's (GSK 1.04%) Arzerra in elderly CLL patient, Incyte's (INCY -0.49%) data on Jakafi in pancreatic cancer, and others.
